Inactive matrix Gla protein is elevated in patients with inflammatory bowel disease

Table 1 Baseline characteristics of inflammatory bowel disease patients and healthy controls

Parameter	IBD group (n = 70)	Control group (n = 60)	P value
Men (n, %)	46 (65.7)	38 (63.3)	0.7781
Women (n, %)	24 (34.3)	22 (36.7)
Age (yr)	40.8 ± 14.9	38.7 ± 12.6	0.3902
Body weight (kg)	77.7 ± 12.5	81.3 ± 13.2	0.1112
Body height (cm)	177.7 ± 8.2	180.1 ± 9.1	0.1322
Body mass index (kg/m2)	24.6 ± 3.5	25.0 ± 2.8	0.4932
Waist circumference (cm)	88.1 ± 12.6	88.0 ± 12.1	0.9972
hsCRP (mg/L)	2.65 (1.0-7.8)	0.75 (0.4-1.75)	< 0.0013
Fecal calprotectin (μg/g)	235 (56.0-658)	-	-
Disease duration (yr)	8.5 (3.5-13.0)	-	-
UCEIS score	6.0 (5.0-7.0)	-	-
SES-CD	10.3 (5.2-13.6)	-	-
mAb therapy (n, %)	48 (68.5%)	-	-

Data are presented as mean ± standard deviation or median or n (%).

¹Chi-squared test.

²t-test for independent samples.

³Mann-Whitney U test. UCEIS: Ulcerative Colitis Endoscopic Index of Severity; SES-CD: Simple Endoscopic Score for Crohn's Disease; mAb: Monoclonal antibody; hsCRP: High sensitivity C-reactive protein.

Table 2 Multiple linear regression model of independent predictors for dephosphorylated and uncarboxylated matrix Gla protein concentration

Variable	β1	SE	t value	P value
Fecal calprotectin (μg/g)	0.06	0.02	3.08	0.003
hsCRP (mg/L)	0.66	0.47	1.41	0.162
Body mass index (kg/m2)	-11.15	5.82	-1.92	0.058
Age (years)	1.87	1.13	1.65	0.102
Waist circumference (cm)	4.35	1.72	2.54	0.013
Disease duration (yr)	-3.96	1.81	-1.84	0.062

¹Unstandardized coefficient β. SE: Standard error; hsCRP: High sensitivity C-reactive protein.